The β2-Adrenoceptor Subpopulation and Its Contribution to Force Generation in Human Ventricular Myocardium

  • M. Böhm
  • B. Pieske
  • P. Schnabel
  • E. Erdmann
Conference paper

Abstract

In the failing human heart, there is a downregulation of cardiac β-adrenoceptors (Bristow et al. 1982, 1984; Ginsburg et al. 1983; Böhm et al. 1988a). As a consequence, the positive inotropic effect of β-adrenoceptor agonist is reduced under experimental (Bristow et al. 1982; Fowler et al. 1986; Böhm et al. 1988a, b) and clinical conditions (Colucci et al. 1988). Increased levels of noradrenaline, imposing a permanent β-adrenergic stimulus on the heart of patients with heart failure (Chidsey et al. 1962, Cohn et al. 1984), are regarded to initiate β-adrenoceptor downregulation. Since noradrenaline primarily stimulates β1-adrenoceptors (Gille et al. 1985) one would expect that β1-adrenoceptors are more affected by downregulation than the β2-adrenoceptor subpopulation. If this is true, the stimulation of β2-adrenoceptors which have been identified in the human myocardium by radioligand-and functional studies (Brodde et al. 1983, 1984, 1986) could be a usefull pathway to increase force of contraction in heart failure. Therefore, cardiac β-adrenoceptors and the β1- and β2-adrenoceptor subpopulation were studied with radioligand binding experiments. Moreover, the effect of the β2-adrenoceptor agonist dopexamine (Brown et al. 1985; Smith et al. 1987) on force of contraction and adenylate cyclase activity was studied in isolated myocardium from failing hearts.

Key words

β2-adrenoceptor Heart failure Positive inotropic effect Human myocardium 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Böhm M, Beuckelmann D, Brown L, Feiler G, Lorenz B, Näbauer M, Kemkes B, Erdmann E (1988) Reduction of beta-adrenoceptor density and evaluation of positive inotropic responses in isolated, diseased human myocardium. Eur Heart J 9: 844–852PubMedGoogle Scholar
  2. Böhm M, Diet F, Feiler G, Kemkes B, Kreuzer E, Weinhold C, Erdmann E (1988) Subsensitivity of the failing human heart to isoprenaline and milrinone is related to beta-adrenoceptor downregulation. J Cardiovasc Pharmacol 12: 726–732PubMedCrossRefGoogle Scholar
  3. Böhm M, Diet F, Feiler G, Kemkes B, Kreuzer E, Weinhold C, Erdmann E (1988) Subsensitivity of the failing human heart to isoprenaline and milrinone is related to beta-adrenoceptor downregulation. J Cardiovasc Pharmacol 12: 726–732PubMedCrossRefGoogle Scholar
  4. Bristow MR, Ginsburg R, Minobe W, Cubiciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB (1982) Decreased catecholamine sensitivity and beta-adrenergicreceptor density in failing human hearts. N Engl J Med 307: 205–211PubMedCrossRefGoogle Scholar
  5. Bristow MR, Kantrowitz NE, Ginsburg R, Fowler MR (1985) Betaadrenergic function in heart muscle disease and heart failure. J Mol Cell Cardiol 17 [Suppl 2]: 41–52PubMedCrossRefGoogle Scholar
  6. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S, Stinson EB (1986) (31- and 132-Adrenergic receptor subpopulatons in non-failing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective ß1-receptor down-regulation in heart failure. Circ Res 59: 297–309Google Scholar
  7. Brodde OE, Karad K, Zerkowski HR, Rohm N, Reidemeister JCh (1983) Coexistence of (31-and (32-adrenoceptors in human right atrium. Direct indentificaton by (I)-125iodocyanopindolol binding. Circ Res 53: 752–758PubMedGoogle Scholar
  8. Brodde OE, O’Hara N, Zerkowski HR, Rohm N (1984) Human cardiac ß-adrenoceptors: both (31- and 132-adrenoceptors are functionally coupled to the adenylate cyclase in the right atrium. J Cardiovasc Pharmacol 6: 1184–1191PubMedGoogle Scholar
  9. Brodde OE, Schüler S, Kretsch R, Brinkmann M, Borst HG, Hetzer R, Reidemeister JCh, Warnecke H, Zerkowski HR (1986) Regional distribution of ß-adrenoceptors in the human heart: coexistence of functional (31- and ß2-adrenoceptors in both atria and ventricles in severe congestive cardiomyopathy. J Cardiovasc Pharmacol 8:1235 —1242Google Scholar
  10. Brown RA, Dixon J, Farmer JB, Hal JC, Humphries RG, Ince F, O’Connor SE, Simpson WT, Smith GW (1985) Dopexamine: a novel agonist at peripheral dopamine receptors and 132-adrenoceptors. Br J Pharmacol 85: 599–608PubMedGoogle Scholar
  11. Chidsey CA, Harrison DC, Braunwald E (1962) Augmentation of the plasma noradrenaline response to exercise in patients with congestive heart failure. N Engl J Med 267: 650–654PubMedCrossRefGoogle Scholar
  12. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T (1984) Plasma noradrenaline as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311: 819–823PubMedCrossRefGoogle Scholar
  13. Colucci WS, Leatherman GF, Ludmer PL, Gauthier DF (1987) ß-adrenergic inotropic responsiveness of patients with heart failure: studies with intracoronary dobutamine infusion. Circ Res 61 [Suppl I1: 82–86Google Scholar
  14. De Lean A, Hancock AA, Lefkowitz RJ (1982) Validation and statistical analysis of a computer modeling method for quantitative analysis of radioligand binding data for mixtures of pharmacological receptor subtypes. Mol Pharmacol 21: 5–16PubMedGoogle Scholar
  15. Gille E, Lemoine H, Ehle B, Kaumann AJ (1985) The affinity of (—)-propranolol for and 132adrenoceptors of human heart. Differential antagonism of the positive inotropic effects and adenylate cyclase stimulation by (—)-noradrenaline and (—)-adrenaline. Naunyn-Schmiedebergs Arch Pharmacol 331: 60–70Google Scholar
  16. Gilman AG (1970) A protein binding assay for adenosine 3’,5’-cyclic monophosphate. Proc Natl Acad Sci USA 67: 305–312PubMedCrossRefGoogle Scholar
  17. Ginsburg R, Bristow MR, Billingham ME, Stinson EB, Schroeder JS, Harrison DC (1983) Study of the normal and failing isolated human heart: decreased response of failing heart to isoproterenol. Am Heart J 106: 535–540PubMedCrossRefGoogle Scholar
  18. Kruse E, Scholz H (1987) Effect of theophylline on myocardial adenylate cyclase activity. Experientia 34: 504–505CrossRefGoogle Scholar
  19. Packer M (1988) Neurohormonal interactions and adaptations in congestive heart failure. Circulation 77: 721–730PubMedCrossRefGoogle Scholar
  20. Sibley DR; Lefkowitz RJ (1985) Molecular mechanisms of receptor desensitization using the beta-adrenergic receptor-coupled adenylate cyclase system as a model. Nature 317: 124–129PubMedCrossRefGoogle Scholar
  21. Smith GW, Hall JC, Farmer JB, Simpson WT (1987) The cardiovascular actions of dopexamine hydrochloride, an agonist at dopexamine receptors and ß2-adrenoceptors in the dog. Jr Pharm Pharmacol 39: 636–641CrossRefGoogle Scholar
  22. Tan LB, Litter WA, Murray RG (1987) Beneficial haemodynamic effects of intravenous dopexamine in patients with low-output heart failure. J Cardiovasc Pharmacol 10: 280–286PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • M. Böhm
    • 1
  • B. Pieske
    • 1
  • P. Schnabel
    • 1
  • E. Erdmann
    • 1
  1. 1.Medizinische Klinik I, Klinikum GroßhadernUniversität MünchenMünchenGermany

Personalised recommendations